- 2025/10/31 Announcement of the date of the board of directors meeting for the third quarter of 2025 financial report
- 2025/10/14 The Final Result of Phase II Clinical Trial of OBP-301 Presented in ESMO Congress 2025
- 2025/08/13 Announcement on Behalf of the Subsidiary, TBG Diagnostics Ltd of the Resolutions of the Shareholders' Meeting
- 2025/08/13 Announcement on Election Results of Directors for Subsidiary TBG Diagnostics Ltd
- 2025/08/11 Announcement of board meeting approved the consolidatedfinancial statements 2025Q2
- 2025/08/05 The Progress Update of the New Drug under Development, OBP-301
- 2025/08/04 Announcement of the date of the board of directors meeting for the second quarter of 2025 financial report
- 2025/07/07 Announcement of Final Non-Prosecution DecisionRendered by the Taiwan High Prosecutors OfficeRegarding Company Executives
- 2025/06/24 The Progress Update of the New Drug underDevelopment, OBP-301
- 2025/06/06 Company has withdrawn its US FDA IND application for PhaseI/II human clinical trials of allogeneic natural killer cells (Magicell-NK)